Lab21 Merges With Cervical Cancer Screening Firm Novacyt
This article was originally published in The Gray Sheet
Executive Summary
The stock-based reverse takeover gives molecular diagnostics firm Lab21 access to Novacyt’s NovaPrep, a second-generation liquid-based cytology screening platform that competes against Roche and Hologic offerings.